Matches in Nanopublications for { <http://bio2rdf.org/drugbank:DB00731> ?p ?o ?g. }
Showing items 1 to 31 of
31
with 100 items per page.
- drugbank:DB00731 type drugbank_vocabulary:Drug assertion.
- drugbank:DB00731 label "Nateglinide [drugbank:DB00731]" assertion.
- drugbank:DB00731 seeAlso DB00731 assertion.
- drugbank:DB00731 seeAlso nateglinide.html assertion.
- drugbank:DB00731 seeAlso sta1565.shtml assertion.
- drugbank:DB00731 seeAlso nateglinide.htm assertion.
- drugbank:DB00731 identifier "drugbank:DB00731" assertion.
- drugbank:DB00731 description "Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound." assertion.
- drugbank:DB00731 title "Nateglinide" assertion.
- drugbank:DB00731 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00052_DB00731 assertion.
- drugbank:DB00731 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00582_DB00731 assertion.
- drugbank:DB00731 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00731_DB01124 assertion.
- drugbank:DB00731 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00731_DB01296 assertion.
- drugbank:DB00731 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00731_DB00976 assertion.
- drugbank:DB00731 drugbank_vocabulary:food-interaction drugbank_resource:4d210308a0d3dc07ad8569993b4e4711 assertion.
- drugbank:DB00731 bio2rdf_vocabulary:identifier "DB00731" assertion.
- drugbank:DB00731 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB00731 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB00731" assertion.
- drugbank:DB00731 bio2rdf_vocabulary:x-identifiers.org DB00731 assertion.
- drugbank:DB00731 drugbank_vocabulary:drugbank-id "APRD00593" assertion.
- drugbank:DB00731 drugbank_vocabulary:drugbank-id "DB00731" assertion.
- drugbank:DB00731 drugbank_vocabulary:x-cas cas:105816-04-4 assertion.
- drugbank:DB00731 drugbank_vocabulary:x-ahfs ahfs:68:20.16 assertion.
- drugbank:DB00731 drugbank_vocabulary:x-atc atc:A10BX03 assertion.
- drugbank:DB00731 drugbank_vocabulary:x-chebi chebi:146727 assertion.
- drugbank:DB00731 drugbank_vocabulary:x-dpd dpd:2245439 assertion.
- drugbank:DB00731 drugbank_vocabulary:x-kegg kegg:C12508 assertion.
- drugbank:DB00731 drugbank_vocabulary:x-kegg kegg:D01111 assertion.
- drugbank:DB00731 drugbank_vocabulary:x-pharmgkb pharmgkb:PA450600 assertion.
- drugbank:DB00731 drugbank_vocabulary:x-wikipedia wikipedia:Nateglinide assertion.
- drugbank:DB00731 drugbank_vocabulary:x-ndc ndc:0078-0351-05 assertion.